DUO delivers for duvelisib

Abstract

In this issue of Blood, Flinn et al report the final results of the phase 3 registration trial DUO,1 which compared the novel PI3Kd,g inhibitor duvelisib with ofatumumab in patients with relapsed refractory chronic lymphocytic leukemia (CLL) and demonstrated a significant improvement in progression-free survival (PFS) with duvelisib. On 24 September 2018, these results led to US Food and Drug Administration (FDA) approval of duvelisib for the therapy of CLL patients after ‡2 prior regimens.